Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$1.01 USD
-0.01 (-0.98%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.00 -0.01 (-0.99%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LCTX 1.01 -0.01(-0.98%)
Will LCTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LCTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LCTX
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates
LCTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Other News for LCTX
Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index
Lineage to Present at 2024 BIO International Convention
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium
Buy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid Financials
Analysts Are Bullish on These Healthcare Stocks: Oncolytics Biotech (ONCY), Lineage Therap (LCTX)